GoAI
Get started
Quantum-Si incorporated logo

Quantum-Si incorporated

QSI

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$0.835

+$0.055 · +7.05%

Aug 21, 4:00 PM ET

QSI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Strong Sell

Exit — multiple negative signals converging

Valuation

18

Overpriced

Momentum

21

Weakening

Sentiment

33

Bearish

Risk resilience

12

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Quantum-Si incorporated operates within the life sciences sector, focusing on the creation of an advanced platform for individual molecule detection. This innovative technology is designed to streamline sample preparation and subsequent sequencing processes. The company offers a unique, proprietary single molecule detection system that draws on advancements from the semiconductor industry. This system is specifically applied to the field of proteomics, paving the way for next-generation protein sequencing. Established in 2013, Quantum-Si's headquarters are located in Guilford, Connecticut.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Jeffrey Alan Hawkins
Listed since
Nov 13, 2020
Employees
145

Market position

Day range

Current $0.835

52-week range

Current $0.835

Open
$0.785
Previous close
$0.78
Volume
7.55M
1.43× average
Average volume
5.27M
Average daily volume
Market cap
165.18M USD
Beta
3.25
Market reference 1
50-day average
$0.8401
-0.60% below average
200-day average
$1.0343
-19.27% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
200.07M USD
P/E (TTM)
-1.8×
P/B (TTM)
1.01×
P/S (TTM)
102.92×
EV / EBITDA
-2.15×
Earnings yield
-46.58%
Free cash flow yield
-44.70%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
35.02%
Operating margin
-5929.72%
Net margin
-6138.26%
Return on equity
-46.02%
Return on assets
-41.26%
Return on invested capital
-43.38%

Financial health

Debt / equity
0.02×
Current ratio
7.64×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1085%-3046%-7177%-11307%Gross margin, FY2023: 45.10%Gross margin, FY2024: 52.32%Gross margin, FY2025: 47.33%Operating margin, FY2023: -10274.58%Operating margin, FY2024: -3550.56%Operating margin, FY2025: -3996.72%Net margin, FY2023: -8868.76%Net margin, FY2024: -3303.04%Net margin, FY2025: -4160.06%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2023 45.10%. Gross margin FY2024 52.32%. Gross margin FY2025 47.33%. Operating margin FY2023 -10274.58%. Operating margin FY2024 -3550.56%. Operating margin FY2025 -3996.72%. Net margin FY2023 -8868.76%. Net margin FY2024 -3303.04%. Net margin FY2025 -4160.06%.

Income trends

Revenue

2.44M USD-20.34%

Operating income

−97.36M USD+10.33%

Net income

−101.34M USD-0.33%
Income trends across reported periods16.61M USD−37.59M USD−91.79M USD−145.99M USDRevenue, FY2023: 1.08M USDRevenue, FY2024: 3.06M USDRevenue, FY2025: 2.44M USDOperating income, FY2021: −96.91M USDOperating income, FY2022: −123.84M USDOperating income, FY2023: −111.17M USDOperating income, FY2024: −108.58M USDOperating income, FY2025: −97.36M USDNet income, FY2021: −94.99M USDNet income, FY2022: −132.44M USDNet income, FY2023: −95.96M USDNet income, FY2024: −101.01M USDNet income, FY2025: −101.34M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2023 1.08M USD. Revenue FY2024 3.06M USD. Revenue FY2025 2.44M USD. Operating income FY2021 −96.91M USD. Operating income FY2022 −123.84M USD. Operating income FY2023 −111.17M USD. Operating income FY2024 −108.58M USD. Operating income FY2025 −97.36M USD. Net income FY2021 −94.99M USD. Net income FY2022 −132.44M USD. Net income FY2023 −95.96M USD. Net income FY2024 −101.01M USD. Net income FY2025 −101.34M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.44M USD3.06M USD1.08M USD——
Cost of goods sold1.28M USD1.46M USD594K USD——
Gross profit1.15M USD1.6M USD488K USD——
Research and development53.76M USD59.64M USD67.03M USD72.06M USD46.58M USD
Selling, general, and administrative44.75M USD50.54M USD44.63M USD42.3M USD50.33M USD
Operating expenses98.51M USD110.18M USD111.66M USD123.84M USD96.91M USD
Interest income8.96M USD————
Interest expense————5K USD
Depreciation and amortization4.45M USD4.6M USD4.16M USD2.58M USD1.04M USD
Operating income−97.36M USD−108.58M USD−111.17M USD−123.84M USD−96.91M USD
Net income−101.34M USD−101.01M USD−95.96M USD−132.44M USD−94.99M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 1 miss, 3 met estimates
Average EPS surprise
+12.12%
11 comparable reports
Latest EPS result
-0.11
Estimate -0.11 · Beat by 2.94%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.07-0.12-0.17-0.22Q1 '25MetQ2 '25BeatQ3 '25MetQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 3, 2025: actual -0.18, estimate -0.18, surprise 0.00%, Met estimate. Q2 2025, reported May 15, 2025: actual -0.11, estimate -0.17, surprise +35.29%, Beat. Q3 2025, reported Aug 5, 2025: actual -0.16, estimate -0.16, surprise 0.00%, Met estimate. Q4 2025, reported Nov 5, 2025: actual -0.17, estimate -0.12, surprise -41.67%, Miss. Q1 2026, reported Mar 3, 2026: actual -0.08, estimate -0.14, surprise +42.86%, Beat. Q2 2026, reported May 7, 2026: actual -0.1, estimate -0.12, surprise +16.67%, Beat. Q3 2026, reported Aug 13, 2026: actual -0.11, estimate -0.113, surprise +2.94%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.13, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.72M1.22M719.4K219.3KQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 3, 2025: actual 1.19M USD, estimate 1.27M USD, surprise -6.09%, Miss. Q2 2025, reported May 15, 2025: actual 842K USD, estimate 1.61M USD, surprise -47.75%, Miss. Q3 2025, reported Aug 5, 2025: actual 591K USD, estimate 599.33K USD, surprise -1.39%, Miss. Q4 2025, reported Nov 5, 2025: actual 552K USD, estimate 599.33K USD, surprise -7.90%, Miss. Q1 2026, reported Mar 3, 2026: actual 451K USD, estimate 761.9K USD, surprise -40.81%, Miss. Q2 2026, reported May 7, 2026: actual 258K USD, estimate 298.67K USD, surprise -13.62%, Miss. Q3 2026, reported Aug 13, 2026: actual 344K USD, estimate 302K USD, surprise +13.91%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 280K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$1.45

73.65% upside
Past 12 months12-month forecastHigh $1.90Average $1.45Low $1.00

QSI news

globenewswire.com

Quantum-Si to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

BRANFORD, Conn., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule protein…

Read source
seekingalpha.com

Quantum-Si incorporated (QSI) Q2 2026 Earnings Call Transcript

Quantum-Si incorporated (QSI) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Quantum-Si Q2 Earnings Call Highlights

Quantum-Si NASDAQ: QSI said it has moved the planned launch of its Proteus protein sequencing platform to the second quarter of 2027 from the end of 2026, citing the need for an additional integrated instrument design…

Read source
zacks.com

Quantum-Si Incorporated (QSI) Reports Q2 Loss, Tops Revenue Estimates

Quantum-Si Incorporated (QSI) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.16 per share a year ago.

Read source
globenewswire.com

Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update

Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new market opportunities for protein sequencing BRANFORD,…

Read source
globenewswire.com

Quantum-Si to Report Second Quarter 2026 Financial Results on August 13, 2026

BRANFORD, Conn., July 27, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule…

Read source

QSI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding QSI

Funds reporting this stock among their holdings, ordered by reported position size.

ARK Genomic Revolution ETF logoARK Genomic Revolution ETFARKG
Market value
5.88M
Weight
0.28%
AUM
1.56B USD
Expense ratio
0.75%
Price / 1D
$49.45+3.80%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.81M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.48M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
983.2K
Weight
0.01%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
356.89K
Weight
0.00%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%
iShares Core S&P Total U.S. Stock Market ETF logoiShares Core S&P Total U.S. Stock Market ETFITOT
Market value
339.75K
Weight
0.00%
AUM
97.17B USD
Expense ratio
0.03%
Price / 1D
$167.97+0.46%
Invesco RAFI US 1500 Small-Mid ETF logoInvesco RAFI US 1500 Small-Mid ETFPRFZ
Market value
330.99K
Weight
0.01%
AUM
2.87B USD
Expense ratio
0.34%
Price / 1D
$55.89+0.87%
Invesco Nasdaq Biotechnology ETF logoInvesco Nasdaq Biotechnology ETFIBBQ
Market value
8.98K
Weight
0.01%
AUM
94.57M USD
Expense ratio
0.19%
Price / 1D
$36.29+1.37%

Continue in GoAI

Research QSI

research.disclaimer